Robert Jeffress: We Allowed Atheists and Infidels to Pervert Our Constitution – Friendly Atheist – Patheos

Posted on by

Not only is America a Christian country, but the Constitution has been perverted by infidels and atheists, according to MAGA cultist and Trump sycophant Pastor Robert Jeffress.

He made the comments on his Pathway to Victory broadcast during a series of episodes earlier this month promoting the Christian Nation myth. In the excerpt below, he was complaining about Supreme Court decisions that removed mandatory Bible readings from public schools.

And heres the question: What has changed? What has changed? In these 150 years,has the Constitution changed and nobody told us? Is that what happened? Of course not. What has happened is we have allowed the secularists, the humanists, the atheists, the infidels, to pervert our Constitution into something our Founding Fathers never intended. And it is time for Americans to stand up and say Enough! Were not going to allow this in our Christian country anymore. It is time to put an end to this.

Its time to once again reiterate that the Bible says far more about welcoming the immigrant and serving the poor and marginalized than anything about abortion or LGBTQ issues which Jeffress also brought up elsewhere in his episodes. (Interestingly enough, helping the poor would also result infewer abortions, a fact Jeffress never seems to care about.)

Pretending we live in a Christian Nation doesnt make it true. Lying about the past wont change reality either. The fact remains if our government treated atheism or Islam the way weve historically treated Christianity, Jeffress would never stop whining about it.

(via Right Wing Watch)

View post:

Robert Jeffress: We Allowed Atheists and Infidels to Pervert Our Constitution - Friendly Atheist - Patheos

Letter: The National Anthem is under attack by the left – Arizona Daily Star

Posted on by

Our National Anthem is once again under attack.

Lets face facts, the Star Spangled Banner was written by a slave owner, is focused on rockets and bombs, and is impossible to sing by normal patriots such as me.

In my early leftist days we wanted Woody Guthries This Land Is our Land. Although a socialist, he was home-grown and sincere, and I could hum along without embarrassment.

We took a hard look at American the Beautiful by Irving Berlin, a Jew born in Russia who immigrated to the US as a child. This uplifting song has found a niche in our American fabric since 9-11.

Leftists now want Image penned by John Lennon, a Brit with Green Card who had a path to citizenship at his untimely death. His song is morally vapid, praising atheism and globalism. Thats not America.

Im sticking with those broad stripes and bright stars. You sing and I will listen with hand over chest.

Disclaimer: As submitted to the Arizona Daily Star.

Get opinion pieces, letters and editorials sent directly to your inbox weekly!

See the original post:

Letter: The National Anthem is under attack by the left - Arizona Daily Star

Rudy Giuliani: Black Lives Matter is going to take away your property and give it to Black people – Media Matters for America

Posted on by

RUDY GIULIANI (HOST): This is not - please, understand this - this is not isolated. This is not spontaneous. This is planned. This is planned by Black Lives Matter, it's funded by Soros to the tune of $30 to $40 million. And the plan is to change your government. To take it away from you. To take away from you a government based on free enterprise. To take away from you your Second Amendment right to bear arms.To take away from you, really, your right to have a religion. Soros is a notorious atheist. Proclaims the fact that he's an atheist. So are Marxists, by the way. It's one of the cores of Marxism, atheism.

And one of the cores of Marxism is no private property. They want your property. They want the government to control it. But they do want one preferred class and that's the people who are -- they're going to get, like, a lifetime salary. And that's going to be -- Black people will get that. And they'll also get to choose property that they want, and that's the reparations for slavery. Except, it'll include Black people that came from the Caribbean. And it's going to get paid by white people who never had anything to do with slavery.

The rest is here:

Rudy Giuliani: Black Lives Matter is going to take away your property and give it to Black people - Media Matters for America

Freaks and Geeks May Have Been A Little Too Real – Film School Rejects

Posted on by

Welcome toPetition Worthy, a biweekly column that revisits canceled TV shows that we wish had a longer lifespan. In some cases, well also make a plea for them to be given another chance. This entry spotlights Freaks and Geeks.

If Paul Feig and Judd Apatow combined their powerhouse talents to create a TV show these days, it would probably be a hit. Back in 1999, though, Feig and Apatow werent Hollywood A-listers, and Freaks and Geeks wasnt the huge success story it should have been.

That said, Freaks and Geeks has left its mark on pop culture. The show helped launch the careers of several stars, including Seth Rogen, Linda Cardellini, and Jason Segel. But giving a break to future Hollywood A-listers isnt the only legacy Freaks and Geeks will be remembered for. The shows ability to resonate with young people is its true special power.

Shows about high school often portray teenage life as exciting and sexy. Dawsons Creek, which was the most popular teen show in the late 90s, is a prime example of that. Freaks and Geeks, meanwhile, provided a more authentic snapshot of adolescence and all of the insecurities that come with it. Furthermore, it did so while being consistently funny.

For Feig, it was important to create a show that reflected the high school experience that he and many others understood. In an interview with Vanity Fair, he explained that his goal was to give young people a show that could guide them through their own coming-of-age journeys.

My friends and I werent popular in high school, we werent dating all the time, and we were just trying to get through our lives. It was important to me to show that side. I wanted to leave a chronicle to make people who had gone through it laugh, but also as a primer for kids going in, to say, Heres what you can expect. Its horrifying but all you should really care about is getting through it. Get your friends, have your support group. And learn to be able to laugh at it.

Freaks and Geeks was created for the outsiders and misfits. But thats most teenagers to some degree. Set in the early 80s, the story revolves around a group of teens who are just trying to make sense of the world. The central characters are Lindsay (Cardellini) and Sam Weir (John Francis Daley), a pair of siblings who lead the titular freaks and geeks of McKinley High.

Lindsay is the gifted student who rejects academics to hang out with a bunch of slackers. She becomes more experimental following the death of her grandmother, who saw nothing just before she passed away. This affects Lindsay, but her newfound sense of atheism makes her a free thinker who questions authority and commands respect from her peers.

The shows decision to openly embrace atheism from the outset spoke volumes about its unconventional approach to storytelling. In a climate where so many teens shows chased commercialism, Freaks and Geeks was unafraid to explore existentialism. The show isnt anti-Christian, but it acknowledges the reality that many teenagers reject such belief systems.

Sam, meanwhile, is the charming nerd who is picked on by the school bullies. His sister has a tendency to fight his battles, and the teachers dont approve of him snitching on other students. He also meets the girl of his dreams, which leads to him becoming accepted in popular social circles for a minute. Then he realizes that he isnt interested in his dream girl because she and her friends are shallow.

In a conventional teen drama, Sam would have fallen in love with the cheerleader and lived happily ever after. They would have brought their respective social groups together and everything would have been rosy. If they did break-up, itd be soap opera-esque and dramatic. Freaks and Geeks simply presents them as curious and incompatible. Such is the nature of young love at times.

Sams romantic relationship also ties into the shows portrayal of sex. In one episode, he wears a V-neck to hide a hickey on his neck. This doesnt sit too well with his girlfriend, who wants him to wear the mark as a badge of honor. Sam is terrified of sex, though, and just wants to preserve his childhood for a while longer. And thats okay.

Freaks and Geeks also has a cast of actors who feel like real people. This is especially apparent in Rogens character. The actor was going through puberty at the time, and his voice was changing. Other actors would have been required to work with a drama coach. Freaks and Geeks showcases this awkward stage of adolescence in its truest form.

NBC executives gave Feig and co. creative freedom going into the show. When Garth Ancier took over as the networks president, however, things turned sour. Ancier arrived from The WB, which had found great success with Dawsons Creek. He wanted a show in a similar vein to the teen hit.

Ancier received a private school education. He didnt identify with the crummy public school dorks in Freaks and Geeks. The network president also wanted the show to have more victories for the characters, which went against the shows warts-and-all sensibilities.

The creators refused to obey the network, and the rest is history. Feig and co. were unwilling to buck to executive demands. This proved to be a death knell, though, as the shows ratings didnt justify a second season. Freaks and Geeks was canceled after 12 of the 18 episodes had aired.

That said, what would have happened if the show continued? The creators have talked about it throughout the years. Lindsay would have gone on tour with the Grateful Dead and experimented with drugs. Sam would have joined the drama club. Nick (Segel) would have been forced into the army. Those stories were just too depressing for NBC back then.

While the show was canceled too soon, at least it continues to find audiences to this day. The trials and tribulations faced by young people are timeless and universal. This is why so many of them continue to identify with the outsiders and misfits in this one-season wonder from 1999.

See more here:

Freaks and Geeks May Have Been A Little Too Real - Film School Rejects

McGovern: Federal govt. should ‘step up’ to address food insecurity – The Recorder

Posted on by

U.S. Rep. Jim McGovern said he doesnt want to see things go back to normal.

Normal wasnt acceptable, he said. Normal was when we had 40 million people in this country who were hungry. We need to do better than normal.

At a remote Town Hall meeting hosted Thursday by Reps. Natalie Blais, D-Sunderland, and Mindy Domb, D-Amherst, McGovern called for the federal government to step up in its efforts to address the nationwide issue of food insecurity.

Two months ago this week, McGovern said, the House of Representatives passed the Health and Economic Recovery Omnibus Emergency Solutions Act, better known as the HEROES Act, in response to COVID-19s impact on the economy, public health, state and local governments, individuals and businesses.

In the previous bills that we passed, it really didnt address the issue of food insecurity and hunger adequately. It didnt do anywhere near enough, said McGovern, D-Worcester. In the HEROES Act ... we included things like boosting the maximum SNAP (Supplemental Nutrition Assistance Program) benefit by 15 percent, increasing the monthly minimum SNAP benefit from $16 to $30, and placing a hold on all the harmful rules that have been proposed by the executive branch, by the Trump Administration, that . literally would have thrown millions of people off the benefit.

As good as the act was, McGovern said, he is still waiting for Sen. Mitch McConnell to schedule a vote in the U.S. Senate.

For two months to do nothing, while people in this country go hungry, is unconscionable, he said.

In Western Massachusetts in particular, the issue of hunger and food insecurity is only getting worse, according to Christina Maxwell of the Food Bank of Western Massachusetts.

Before the pandemic began, in Western Mass., approximately 1 in 10 people was food insecure, Maxwell said. By the end of this year, we estimate its gong to be 1 in 7 people, including 1 in 4 kids.

She said the Food Bank of Western Massachusetts and 174 member agencies food pantries, meal sites, brown bag programs have served an average of 16 percent more people each month since the pandemic began than at the same time last year.

Were seeing a lot of people who have never needed to get help for finding food before, so they dont know where to go, they have no idea who to call to ask, they dont know how to find these places, she said. So weve been trying to do a lot of outreach to the general community and let people know, Were here, weve got food and we can help you find resources, too.

A number of those resources were represented at the remote meeting on Thursday, including representatives from the Amherst Survival Center, Granby to Go and The Brick House Community Resource Center in Turners Falls.

Erin McAleer, executive director at Project Bread, said she sleeps well at night knowing McGovern is down in Washington, D.C., working on behalf of organizations like her Boston-based nonprofit.

This was a crisis before COVID. Theres no reason that anybody in America should have been hungry prior to COVID-19, McAleer said, noting that the crisis has only gotten worse since the pandemic hit.

She said the good news is there are programs out there, including food pantries, food banks, supplemental assistance programs, school meal sites and Meals on Wheels.

Still, she echoed McGoverns push for the U.S. Senate to take up the HEROES Act.

Our congressional delegation is strong on this, she said. So if you dont want to call them, call friends in other states and tell them to push for it, because it matters to families in Massachusetts that we increase the SNAP allotment.

McGovern said he was inspired to hear about the work being done by various organizations across the state.

For all the great work you all collectively do, he said, speaking to attendees at the meeting who work or volunteer at food banks, food pantries and other social service providers, it is not a substitute for the federal government actually stepping up to the plate and funding these programs in a way that will make a real difference.

He emphasized the importance of remaining focused on addressing the issue of food insecurity.

People are going hungry, he said. We need to make sure people know where they can get relief and we need to be focused on changing our policies.

Mary Byrne can be reached at mbyrne@recorder.com or 413-772-0261, ext. 263. Twitter: @MaryEByrne

Link:

McGovern: Federal govt. should 'step up' to address food insecurity - The Recorder

Coronavirus death rate: what it is, what it isn’t and why US can expect it to rise – The Guardian

Posted on by

Cases of Covid-19 are surging across the United States sun belt, the region from southern California to Florida. More than 137,000 Americans have died, and more than 3 million have been infected.

But as cases have surged, daily deaths associated with the pandemic have not risen to the seismic numbers seen in April, when New York City was gripped by the virus.

More than 2,429 were reported dead due to coronavirus on 21 April nationally, one of a set of horrific days that month. On 17 July 977 people were reported dead, even as infections increase rapidly in the south and west.

Politicians have seized on this, including Donald Trump, who has perpetuated falsehoods about the death rate even as hospitals across the region begin to fill.

First, lets talk about what it does not the likelihood that an infected person will die. That measurement is called the case fatality rate, and is the reason we know Covid-19 causes far more severe disease and death than a typical flu.

Its very important to understand the lethality of a pandemic, said Dr Howard Markel, a pandemic historian, expert in infectious diseases and a pediatrician at the University of Michigan School of Public Health.

Covid-19 has a high case fatality rate, which is the reason authorities believe it is worth disrupting our lives to stop it. Like many metrics with Covid-19, the case fatality rate is based on preliminary data which may be incomplete.

To find the case fatality rate, divide the total number of people diagnosed with Covid-19 by the number of people who have died. It is easy. The reason it is probably not accurate is because the total of confirmed Covid-19 cases will not represent all cases.

Some people will have the disease, but never get tested. Perhaps because they have no symptoms, perhaps because they fear paying for a test, or perhaps because no tests are available. There are myriad reasons. The number of people confirmed to have died of Covid-19 is also almost certainly an undercount.

For these reasons, the case fatality rate does not accurately represent an infected persons risk of death from Covid-19, although estimates put it between 3 and 5%, according to Markel.

The death rate often referred to by Trump is the number of deaths in proportion to a population. In other words, it measures the risk of death from Covid-19 across a whole population.

Of the 20 nations currently most affected by Covid-19, the United States has the second-highest death rate at about 42 people killed by Covid-19 per 100,000, according to Johns Hopkins Universitys Covid Resource Center tracking project. Only the United Kingdom is higher, with 67 people per 100,000 killed by Covid-19. Of all countries in the world, the United States has the sixth-highest death rate, behind Belgium, the UK, Spain, Italy, Sweden and France.

But keep in mind, experts view this data skeptically as well.

People in my line of work have to take this data with a grain of salt, said Dr Steven Woolf, a professor in the department of family medicine and population health at Virginia Commonwealth University.

Typically, death rates from specific diseases take years to be issued by the US Centers for Disease Control and Prevention. Now, they are being rushed out in a crisis, and it will probably be a long time before we can make solid apples to apples comparisons.

The short answer is: no. Many experts are worried, and predict a surge of deaths to come, in line with infection and hospitalization rates.

There are a number of reasons why the death rate might not have risen yet, but the most important is that death is a lagging indicator.

If you look at the beginning of the pandemic in the US, it wasnt really until the middle of April when we saw the huge spike in deaths in New York and New Jersey, said Woolf. Im hopeful that the fact that we havent seen the death count start climbing in an exponential way is because were more effective at treatment now, but Im quite worried thats coming.

For other reasons, the death rate may never reach the levels seen in New York City. The average age of Covid-19 diagnosis has dropped since the beginning of the pandemic. That means the outbreak is now being driven by young people who are less likely to die from Covid-19, which could be a factor in the declining death rate.

Second, the surge is spread over a wider geographic area than the one that overwhelmed hospitals in New York City. Mortality may rise as hospitals become overwhelmed and have fewer resources, experts at Johns Hopkins have said. If hospitals become overwhelmed, nurses may be forced to care for a higher number of patients, and care may suffer.

Last, there are unknowns. The coronavirus has been with us since January, or roughly seven months. It is still novel.

The CDC is forecasting up to 170,000 Americans could have died of Covid-19 by 8 August, with the worst-affected states coinciding with the worst outbreaks of disease or where residents have the worst health. Arizona, Florida, Idaho, Montana, Oklahoma, South Carolina, Tennessee, Texas, Utah, the Virgin Islands and West Virginia are expected to bear the most deaths.

We see a pattern where the states ignored public health guidance and opened up too early, said Woolf. The result is that were seeing not only a surge in cases in a public health crisis in those states, but the very economy they were trying to preserve by opening early is now being put in jeopardy.

Even the extraordinary toll Covid-19 has already taken is likely to be a huge undercount. In research published in the Journal of the American Medical Association Network, Woolf and his co-authors reported up to one-third of Covid-19 deaths may be missed in official tallies. Although the study only looked at one eight-week window, if the findings hold true, it could represent tens of thousands of Americans nationally.

You dont really have to be an epidemiologist to look at the numbers on the nightly news and know something is going terribly wrong in the United States, said Woolf. Its not a subtle difference you can wash away with statistical analysis.

Read this article:

Coronavirus death rate: what it is, what it isn't and why US can expect it to rise - The Guardian

UND campus in shock after recently retired Provost Tom DiLorenzo is killed in South Carolina robbery, arrests made – Grand Forks Herald

Posted on by

DiLorenzo was with his wife, Suzanne Austin, the College of Charlestons new appointed provost, at approximately 6:15 a.m. when two men armed with a handgun demanded money from the couple in downtown Charleston.

DiLorenzo was shot during the robbery attempt and was taken to a local hospital, where he died, according to a police report. Austin wasnt injured.

The investigation is ongoing.

Late Friday night, Charleston Police announced the arrests of two juvenile males. The suspects, ages 15 and 16, have both been charged with murder and attempted armed robbery. One is also charged with possession of a deadly weapon during the commission of a violent crime.

The news, which broke around noon Friday, sent shockwaves across UND and the Greater Grand Forks community. The incident became national news, with at least one national network reporting it during a 5:30 p.m. newscast.

DiLorenzo, 63, retired as provost of UND on June 1 after having been at the university for seven years.

His death comes six weeks after he retired from UND and a few weeks after he and his wife moved to Charleston.

Joshua Wynne, former interim president of UND and dean of the medical school, remembered DiLorenzo for his hard-working nature and commitment to UND.

To earn your retirement and then six weeks later be gone is incredibly sad, Wynne said. I'm sure he was working until the minute he walked out the door and locked it.

He cared deeply about UND, Debbie Storrs, interim provost at UND, said. "He encouraged us to think differently, look forward and envision a better university. He was committed to equity and hired many women into leadership positions.

Storrs said DiLorenzos new adventure was abruptly ended.

It is hard to put to words the sadness, especially in the world we live in today, she said. He will be missed. His impression on UND is felt, and we will continue to think forward.

Former UND Provost Tom DiLorenzo. (UND provided photo)

Gracie Lian, former student body president, said she was in a state of shock Friday after hearing the news.

He was always so warm and welcoming and ready to listen to the student voice, which I think was so important, Lian said, speaking of her time interacting with DiLorenzo. He really did care about student opinion on things.

Lian said she was especially impressed with DiLorenzos leadership during the COVID-19 pandemic as he was wrapping up his final months at UND. She said he was always reaching out to student leaders to ensure they were comfortable with the plans.

Tom worked tirelessly to help better UND, Matthew Ternus, UND student body president, told the Herald.

He said DiLorenzo was always a caring person who was ready to listen.

Tom was a servant leader during his time at UND, he said.

DiLorenzo served under presidents Robert Kelley and Mark Kennedy during his time at UND. He also served under interim presidents Ed Schafer and Wynne.

He arrived at UND in 2013 and worked to advance and lead initiatives to increase student retention and improve graduation rates. He was a central figure in the development of UND's strategic plan.

Former UND Provost Thomas DiLorenzo is pictured in this 2016 file photo. Jesse Trelstad/ Grand Forks Herald

When his retirement was announced in February he was lauded for his work with UNDs budget and knowledge of the university.

With his superhuman work ethic, Tom gave his heart and soul to the university up until his very last day at UND, said UND President Andrew Armacost, who assumed the president's role in June. He led the universitys response to the COVID-19 pandemic. He initiated programs that strengthened ties between UND and the Grand Forks community. And to improve the academic experience for UND students, he implemented programs that have resulted in better graduation and retention rates. Tom did all that was asked of him and then more. It was the kind of person he was.

During his time as interim president, Wynne effectively had three jobs: interim president, dean of the medical school and vice president of health affairs. Wynne said DiLorenzo made those jobs a little easier.

I think it's a true statement to say that I would not have been able to do all three of those jobs if it were not for the outstanding efforts of Provost DiLorenzo, Wynne said. He was incredibly hard working, of high integrity and tried to do the right thing.

North Dakota University System Chancellor Mark Hagerott said DiLorenzo was killed in an act of senseless violence. He said DiLorenzo was a key leader at UND.

He was a source of stability for UND, he said. He was also an intellectual leader in North Dakota as he pioneered new programs in robotics, cyber science and digital analytics.

Hagerott met DiLorenzo when Hagerott was serving at the U.S. Naval Academy Cyber Center, and said DiLorenzo was the first academic leader who encouraged him to return to North Dakota to serve in the university system.

Former UND President Mark Kennedy also expressed sadness Friday.

Tom cared, Kennedy said in a statement. He cared about his family. He cared about delivering on the mission of higher education to open up opportunities for students and the community.

DiLorenzo championed innovations that led to greater access to higher education for students, Kennedy said.

It was never about him, it was about the students, the faculty, the university, he said. The world is a better place because Tom lived.

Grand Forks Mayor Brandon Bochenski said the news of DiLorenzos death came as a great shock to our community. Bochenski said he and his wife, Jenny, are praying for DiLorenzos family and friends, as well as the many in Grand Forks that were fortunate to have known him.

Because of Dr. DiLorenzos dedication and the bonds he created, the path has been paved for a bright and prosperous future on campus and with UNDs partners, Bochenski said. Our community could not have been more blessed to have had such a strong advocate and leader.

Grand Forks City Administrator Todd Feland said he had the honor and privilege to work closely with DiLorenzo on a handful of strategic projects that are now hallmarks of the Grand Forks Town and Gown relationship.

Feland pointed to the internship program between the city and the university, research partnerships, the Coulee to Columbia infrastructure project and the Main Street GF Challenge as examples of those projects. Those projects would not have happened without DiLorenzos work ethic, greater-good attitude, and ability to work effectively with community stakeholders, Feland said.

He was a driving force in this community and this news hurts on a personal level, Feland said.

In a statement, College of Charleston President Andrew Hsu said DiLorenzo and his wife had moved to Charleston only a few weeks ago.

Tom was celebrated not only for his collaborative leadership style, but also his belief in experiential learning and how the city of Grand Forks served as an extension of the UND classroom, Hsu wrote. Given time, Tom would have seen parallels of that dynamic here in Charleston as well.

See original here:

UND campus in shock after recently retired Provost Tom DiLorenzo is killed in South Carolina robbery, arrests made - Grand Forks Herald

New data from MeiraGTx help bolster J&J’s gene therapy bet – BioPharma Dive

Posted on by

Dive Brief:

Thus far, Johnson & Johnson has not been a major player in gene therapy. Fellow large pharmas Roche, Novartis and Pfizer have each made more sizable bets, while biotechs like Bluebird bio, Sarepta and BioMarin have amassed pipelines of gene-based treatments, some of which are nearing regulatory approvals in the U.S.

Still, J&J has signaled some interest in gene therapy through partnerships, the most notable of which is its 2019 alliance with MeiraGTx. The $440 million pact gave J&J rights to a portfolio of treatments the biotech is developing for inherited retinal diseases.

The gene therapy reported on Friday at the annual meeting of the American Society of Retinal Specialists is one of those treatments and, given the results, likely the first that will be headed to late-stage testing.

Retinitis pigmentosa describes a group of diseases in which the light-sensing photoreceptor cells in the back of the eye deteriorate, leading to vision loss and potentially total blindness. The X-linked form, which mainly affects boys, is particularly severe and accounts for some 10% to 20% of cases. Visual deterioration typically begins in childhood, progressing to legal blindness at a median age of 45 years. A majority of those cases are caused by mutations to the RPGR gene.

No treatments are available to help stop the erosion of vision in XLRP patients. But the programs from Biogen acquired via its $800 million buyout of Nightstar Therapeutics and AGTC could change that, showing encouraging early results.

These therapies deliver a functional form of the RGPR gene into the eye, which then produces proteins meant to prevent photoreceptors from degenerating. So far, both of those gene therapies have shown an ability to increase retinal sensitivity in some, but not all patients.

Results published in Nature Medicine earlier this year, for instance, showed six of 18 patients injected with Biogen's gene therapy in an early-stage trial had improved ability in peripheral vision what's known as the visual field six months after treatment.

MeiraGTx and J&J, meanwhile, enrolled into their study 10 adults with XLRP caused by an RGPR mutation and delivered the gene therapy into one eye, with each patient's other eye serving as a control. The trial's goal was to show treatment is safe and to pick the best dose for further testing.

Five of the seven patients who received a low or medium dose had a meaningful improvement in multiple evaluations of retinal sensitivity six months after treatment. Signs of effectiveness were seen after three months, and either held up or improved with more follow-up.

In two of three patients given a high dose, however, the companies observed evidence of inflammation that they said contributed to "decreased activity" of the gene therapy. The inflammation, which wasn't seen at the lower doses, was managed with a course of steroids.

"The data look promising since they report improvement in retinal sensitivity across the visual field," Sherry Bass, a professor at SUNY College of Optometry in New York and a retinal disease researcher who isn't involved in the trial, wrote in an email to BioPharma Dive. XLRP patients lose their peripheral vision early in life, "so this is an exciting finding," she said.

Trial investigator Michel Michaelides, a professor of ophthalmology at University College London, said that the results show the gene therapy has "the potential to stabilize or slow progressive vision loss." More follow-up will be needed to bear that out, however.

The two companies aim to advance the treatment into a Phase 3 trial called Lumeos. Two other gene therapies from the pact, for forms of achromatopsia, or color blindness, are in Phase 1 testing.

MeiraGTx shares ticked up about 7% in early trading.

Read the rest here:

New data from MeiraGTx help bolster J&J's gene therapy bet - BioPharma Dive

WHO drafting paper on cell and gene therapies – Bioprocess Insider – BioProcess Insider

Posted on by

Regulators in high-income countries have a responsibility to help health authorities in low- and medium-income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDAs biologics centers director Peter Marks.

The World Health Organization plans to soon issue a white paper proposing a harmonized regulatory framework for cell and gene therapy products, according to Peter Marks, director of the US Food and Drug Administrations Center for Biologics Evaluation and Research. Such a framework is considered necessary for facilitating access to these products for patients in low- and medium-income countries and to ensure their commercial viability.

Marks discussed the WHOs plans and described some of the global regulatory challenges in bringing cell and gene therapies to market in at a 30 June webinar sponsored by the Parenteral Drug Association on advanced therapy medicinal products, where he also discussed some of the evolving regulatory requirements for these products in high-, middle- and lower-income countries.

Image: iStock/diegograndi

Marks, a proponent of using regulatory convergence to increase access to novel therapies, asserted that there is a responsibility for regulators in high-income countries to help regulators in low- and medium-countries develop the framework necessary so that some of these products are brought forward in their countries and are appropriate and are safe.

As he explained at a cell and gene therapy policy meeting in November, Marks expects that regulatory convergence among high-income countries could help facilitate commercial availability and pave the way for the use of gene therapies in low- and middle-income countries. He further suggested then thatlow- and middle-income countries adopt something akin to the WHOs prequalification process for vaccines.

In the high- and middle-income countries, the regulatory frameworks for cell and gene therapies are in a state of flux, Marks said. For cell therapies, there is a lack of alignment of regulations in high-income countries, while for gene therapies, there are more similarities.

At international meetings of regulators, the one thing that everyone can agree on is that the existing frameworks are not permanent and that some markets under-regulate while others over-regulate these products.

Yet in low- and middle-income countries, there is no framework at all. For these countries, it can be quite challenging for regulators to devise a framework from scratch. The issue that comes up is that with low- and middle-income countries, they have no experience with cell and gene therapies. If you have to develop regulations out of nothing, it can be quite challenging. When you think about it, small countries have a regulatory agency that consists of a few dozen people.

Rather than having these health authorities devise regulations from scratch, it would be better to leverage a harmonized regulatory framework that has already been developed by other higher-income countries that have more experience in novel therapies.

Marks is on the WHO team that is developing the white paper, or unified regulatory schema, for regulatory convergence on cell and gene therapies.

He said he hopes the white paper will bring some order to this area. The team was making a lot of progress on this before COVID-19 came along, and he expects that the WHO will be publishing this paper in the not too distant future.

Marks said that some possible areas of regulatory convergence could include preclinical study requirements for toxicology studies, environment assessments, manufacturing information, clinical outcomes and inspectional requirements.

The idea for the white paper emerged from a September 2018 meeting of the International Conference of Drug Regulatory Authorities (ICDRA) in Dublin, Ireland.

ICDRAs press release from the meeting said that the WHO would develop with member states a current state of the art document capturing areas where agreement among experienced regulatory authorities exists, noting where harmonization has yet to be achieved, and documenting existing areas of uncertainty; areas covered could include definitions, quality attributes, standards and clinical development pathways.

ICDRA was established in 1980 to bring together regulatory authorities from WHO member states to strengthen collaboration and develop international consensus on regulatory priorities.

Marks said that global regulatory convergence for these products will help ensure that the markets for cell and gene therapies are large enough for commercial viability.

Many gene therapies for ultra-rare diseases target small patient populations enrolling up to 100 patients a year. One country may not have enough patients with a rare disorder to make it commercially viable for a company to launch the product. However, Marks said, if you market across countries you can get to that commercial viability.

Marks emphasized, as he had at the November cell and gene therapy policy meeting, that sponsors should ask officials with other authorities such as the European Medicines Agency to join some some of their meetings with the US FDA as a way to come together to develop enough national markets for the scale required to make many cell and gene therapies viable.

At the PDA webinar, Marks encouraged sponsors to promote convergence by inviting other regulators to attend their pre-IND Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meetings with the FDA. This could go a long way toward educating other authorities on how the FDA assesses potential cell and gene therapy products.

CBER announced in June 2018 the implementation of the INTERACT program, which is intended to help accelerate development and approval of novel biologics and other products reviewed by the center.

We are perfectly happy if a sponsor invites other regulators to listen in on early meetings, said Marks. We have no problem with regulators from other countries listening in on these meetings because it could orient them to some very interesting products that they otherwise would not have exposure to.

Read the original post:

WHO drafting paper on cell and gene therapies - Bioprocess Insider - BioProcess Insider

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -…

Posted on by

(MENAFN - iCrowdNewsWire) Jul 17, 2020

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers), Forecast to 2025

Gene Therapy Market Landscape

The Gene Therapy Market size in 2018 was valued at USD 524 million. It is likely to grow at a whopping 40.7% CAGR by 2025, as per the Market Research Future's (MRFR) new report. Gene therapy comprises replacing, repressing, and repairing dysfunctional genes that cause disease. The aim of this promising treatment is in re-establishing the normal function. This therapy helps to treat different genetic diseases such as inherited disorders, namely cancer & viral infections, and some specific genetic diseases, namely muscular dystrophy & cystic fibrosis.

Numerous factors are propelling the global gene therapy market growth. These factors, as per the new MRFR report, comprise increasing funds for gene therapy research, availability of favourable reimbursements, increasing cases of cancer & other target diseases, and strategic collaborations & product launches made by key players for staying ahead in the competition. Besides, rising cases of target diseases, large investments made by top market players, and robust product pipeline are also adding gene therapy market growth.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

On the contrary, strict regulatory policies coupled with high product development cost are factors that may deter the gene therapy market growth over the forecast period as per the gene therapy market forecast.

Gene Therapy Market Segmentation

The global gene therapy market has been segmented based on indication, product, and end user.

By product, the gene therapy market is segmented into yescarta, zynteglo, luxturna, imlygic, kymriah, zolgensma, strimvelis, and others.

By indication, the gene therapy market is segmented into oncology, genetic disorders/diseases, and others. Among these, the oncology segment will have a major share in the market over the forecast period. The robust cancer gene therapy pipeline, coupled with surging cancer cases, is adding to the growth of the segment.

By end user, the gene therapy market is segmented into hospitals and clinics, the specialty treatment centre, & others. Among these, hospitals & clinics will lead the market over the forecast period. The burgeoning number of hospitals, coupled with hospitals & clinics being the foremost choice to treat diseases, is boosting the growth of this segment.

Gene Therapy Market Regional Analysis

Based on the region, the global gene therapy market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will have lions share in the market over the forecast period for the rising cases of chronic diseases, increasing healthcare expenditure, advanced & innovative healthcare infrastructure, presence of eminent market players, and availability of favorable reimbursements.

The global gene therapy market in Europe is predicted to have favorable growth over the forecast period for industry players coming up with innovative product launches, top companies in the region extending product distribution by securing approval from various regulatory bodies, and increasing expenditure for gene and cell therapy companies in the UK.

The global gene therapy in the Asia Pacific region is likely to grow at a fast pace during the forecast period. The rising government initiatives for the healthcare sector development, presence of top market players in the region, launch & approval of various gene therapy products, rising prevalence of chronic diseases, and growing awareness about gene therapy are adding market growth.

The global gene therapy market in the Middle East and Africa is predicted to hold the smallest share over the forecast period for restricted healthcare infrastructure in the region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-839

Gene Therapy Market Key Players

Eminent players in the global gene therapy market include Orchard Therapeutics plc (UK), Novartis AG (Switzerland), Lonza (Switzerland), CEVEC (Germany), Amgen, Inc. (US), Gilead Sciences, Inc. (US), Thermo Fisher Scientific Inc. (US), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US),and uniQure N.V (Netherlands).

Table Of Contents

Chapter 1. Report Prologue

Chapter 2. Gene Therapy Market Introduction

Definition

Scope Of The Study

Research Objective

Assumptions

Limitations

Chapter 3. Research Methodology

Introduction

Primary Research

Secondary Research

Market Size Estimation

Chapter 4. Gene Therapy Market Dynamics

Drivers

Restrains

Opportunities

Challenges

TOC Continued

Browse More Healthcare Research Reports at:

Intraoperative Neurophysiological Monitoring Market Trends, Size and Application, By Type (EEG, EMG and Evoked Potential (EP)), Method (Invasive, Non-Invasive and Minimally Invasive), Source (In-house, Outsource and Tele-Health), Procedure (Spinal, Neurovascular, Orthopedic, Otolaryngology Surgery, Urology and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast to 2027https://www.marketresearchfuture.com/reports/intraoperative-neurophysiological-monitoring-market-729

Healthcare IoT Security Market Research Report: Information by Component (Solution and Services), Solutions Type (Analytics, Encryption, Data Loss Protection, Identity and Access Management and Unified Threat Management), Service Type (Consulting Services, Risk Assessment Services, Design & Integration Services and Managed Security Services), Security Type (Application, Cloud, Endpoint and Network), Application (Pharmaceutical, Medical Devices and Biotechnology) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025https://www.marketresearchfuture.com/reports/healthcare-iot-security-market-946

Ultra-low Temperature Freezers Market: Information by Type (Upright, Chest), Degree of Cooling (-41C to -86 C Freezers, -87C to -150 C Freezers), Application (Blood & Blood Products, Biological Samples, Drug Compounds, Others), End-User (Bio-Banks, Hospitals & Clinics, Academic & Research Laboratories, Others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027https://www.marketresearchfuture.com/reports/ultra-low-temperature-freezer-market-1813

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

See the rest here:

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -...

The Global Viral Vector & Plasmid DNA Manufacturing Market is Expected to Reach US$ US$ 2247.7 Million by 2027 From US$ 459.4 Million in 2019 -…

Posted on by

NEW YORK, July 16, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05932695/?utm_source=PRN

Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth.Additionally, growth in the global healthcare market is likely to have a positive impact on the market in coming years.

However the high cost associated with gene therapy is the major factor hindering the market growth.

Gene therapies offer an effective way for the treatment of genetic diseases, the acceptance and awareness of gene therapy continues to grow, especially in developed regions.The increase in awareness of gene therapies leads to market entry of new and established players for manufacturing various gene therapy technologies.

For instance, according to a study published by Alliance for Regenerative Medicine in 2018, the number of gene therapy-related clinical trials witnessed growth of an estimated 18.0% compared to the previous year across the world. This growth in the number of clinical trials indicates rise in awareness and massive investments.

Established companies, healthcare organizations, and research institutes are focusing on spreading awareness related to gene therapies as they offer a modern way of disease treatment.For instance, in 2018, Alliance for Regenerative Medicine announced the launch of a new foundation to promote comprehensive understanding and acceptance of gene therapies.

This newly formed organization will work to grow public awareness and benefits of certain gene therapy-based aspects such as cell therapy, tissue-engineering, gene editing, and organ regeneration.

The global viral vector & plasmid DNA manufacturing market is segmented by product and application.Based on product, the viral vector & plasmid DNA manufacturing marketis segmented into viral vectors and non-viral vectors.

The viral vectors segment held the larger share of the market in 2019 andis anticipated to register the higher CAGR during the forecast period.Based on application, the viral vector & plasmid DNA manufacturing markethas been segmented into cancer, inherited disorders, viral infections, and others.

The cancersegment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period.

National Institutes of Health, World Health Organization (WHO), European Medical Association, Centers for Disease Control and Prevention, Canada Foundation of Innovation, Contract Research Organizations, and Dubai Health Authority are some of the essential secondary sources included in the report.

Read the full report: https://www.reportlinker.com/p05932695/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Continue reading here:

The Global Viral Vector & Plasmid DNA Manufacturing Market is Expected to Reach US$ US$ 2247.7 Million by 2027 From US$ 459.4 Million in 2019 -...

Covid-19 Recovery: Outlook on the Worldwide Gene Therapy Industry to 2025 – Cole of Duty

Posted on by

Global Gene Therapy Market Research Report 2020: COVID-19 Outbreak Impact Analysis

Brand Essence Market Research has developed a concise study on the Gene Therapy market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline.

Download Sample PDF (including full TOC, Tables, and Figures) of Gene Therapy Market Research 2020-2026:- https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72699&RequestType=Sample

Global Gene therapy market is valued at USD 0.67 Billion in 2018 and expected to reach USD 5.18 Billion by 2025 with the CAGR of 33.9 % over the forecast period. Increasing prevalence of the cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure is further driving Gene therapy market.

Gene Therapy is associated with the experimental technique that uses genes to treat or prevent disease. In the future, this system could permit doctors to treat a condition by inserting a gene into patients cells rather than exploitation medication or surgery. Gene therapy replaces a faulty gene or adds a new gene in an attempt to cure disease or improve bodys ability to fight disease. Gene therapy holds potential for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. For example, suppose a brain tumor is forming by rapidly isolating cancer cells.

Global gene therapy market report is segmented on the basis of Therapy type, Vector Type, application, and regional& country level. Based upon Therapy type, gene therapy market is classified as somatic and germline. Based upon Vector type Gene Therapy Market is classified into non-viral vectors and viral vectors. Based upon Application Gene therapy market is classified into Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others.

The regions covered in this Global Gene therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Gene therapy is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Gene therapy Market ReportsGlobal Gene therapy market Report covers prominent players are like Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Increasing prevalence of cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure is expected to grow Gene therapy market. Growing prevalence of cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure coupled with the increasing application of public health and clinical facilities is expected to drive Gene therapy market. As this therapy is transforming the current approaches to promote the excellence in health and prevent from cardiovascular diseases such as cancer and diabetes. In 2017, it is projected that around 14% (more than 34 million adults) were current smokers. While People with diabetes comprise 8.8% of the worlds population and IDF predicted that the number of cases of diabetes will rise to 642 million by 2040. In low-income countries, mainly in Africa, the older population faces a considerable burden of both non-communicable and communicable diseases. High cost of gene therapy treatment and unwanted immune responses such factors hindering the growth of gene therapy market. Technological Advancements leading to provide better technological procedures is the lucrative opportunity for gene therapy market in forecast period.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Gene Therapy Market.

Key Benefits for Gene Therapy Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

By Disease Indication Cancer Genetic disorders Cardiovascular diseases Ophthalmology Neurological conditions Others

By Type of Vectors Viral vectors Non-viral vectors

By Type of Cells Somatic cells Germline cells

By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

North America is dominating the Gene therapy Market North America is dominating the gene therapy market during the forecast period due to increasing healthcare expenditure coupled with advancement of technologies. The majority of gene therapies clinical trials recognized targeted cancer diseases. In the US, around 66.81% of gene therapy clinical trials are carried out. While all other countries participated in a small percentage of the trials such as 9.45% in the UK, 3.95% in Germany and around 2% each in Switzerland, France, China, and Japan. Globally, regeneration medicine companies providing Gene cell therapy and tissue engineering for therapeutic developers is expected to grow gene therapy market in this region.

Gene Therapy Market Key Players: Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc. Boehringer Ingelheim International GmbH uniQure N.V. bluebird bio, Inc. Celgene Corporation Others

This comprehensive report will provide:

Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

>>>>Get Full Customize report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72699&RequestType=Customization

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The Essential Content Covered in the GlobalGene Therapy Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report provides a 6-year forecast (2020-2026) assessed based on how the Gene Therapy market is predicted to grow in major regions like USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Strategic Points Covered in TOC:

Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Gene Therapy market.

Chapter 2:Evaluating the leading manufacturers of the global Gene Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4:Presenting global Gene Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Read More: https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Gene-Therapy-Market-Share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at[emailprotected]

Top Trending Reports:

https://technologyindustrynews.com/railway-management-system-market-2020-by-advanced-technologies-growth-opportunities-key-players

https://technologyindustrynews.com/restaurant-management-software-market-share-size-analysis-with-industry-segment-2020-manufacturers

https://industrywatchnews.com/porcine-vaccines-market-scenario-strategies-growth-factors-opportunities-analysis-and-forecast-by

https://industrywatchnews.com/cell-banking-outsourcing-market-size-overview-by-industry-trends-share-growth-factor

https://industrywatchnews.com/artificial-embryo-market-overview-by-share-size-market-players-revenue-and-product

Continued here:

Covid-19 Recovery: Outlook on the Worldwide Gene Therapy Industry to 2025 - Cole of Duty

2020 to 2027 Global Gene Therapy Market Report 2020 COVID 19 Impact Analysis Updated Edition Top Players Include, Kite Pharma, BioVex, Novartis, Spark…

Posted on by

Global Coronavirus pandemic has impacted all industries across the globe, Gene Therapy market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Gene Therapy market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report.

Checkout Inquiry for Buying or Customization of Report: https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#download_report.

The number of coronavirus cases is increasing rapidly which has not only taken a number of lives but has also affected the global economic structure. The Coronavirus Disease Pandemic (COVID-19) has affected all parts of the world. This virus has changed all the market conditions and hampers the growth of the various sectors of the global Gene Therapy market. The report covers rapidly altering market scenario due to COVID-19 and market fluctuation during the forecast period. Cognitive Market Research has published Gene Therapy market report accordingly.To Get Detailed Analysis Mail us @ [emailprotected] or call us on +1-312-376-8303.

The global Gene Therapy market report covers in-depth impression of regional level break-up, leading growth rate territory, countries with the highest market share, geographical break-up, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The report also offers comprehensive evaluation of the market, current growth factors, focused opinions and industry certified market data.

Request Free Sample Copy @ https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#download_report

The global Gene Therapy Market can be segmented into various type and application. All the type and application segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Gene Therapy market.

Global Gene Therapy Market Segmentation: By Types Ex Vivo, In Vivo

Global Gene Therapy Market segmentation: By Applications Cancer Diseases, Hematological Disease, Hereditary Disease

Manufacturers are facing continued downward pressure on demand, production and revenues as the COVID-19 pandemic strengthens.manufacturers should be prepared for major global supply chain disruptions. Thus, some of the key players are mainly focusing on research & development to provide inovative products to clint.Major Key Players mentioned in the report are: Kite Pharma, BioVex, Novartis, Spark Therapeutics

Global Gene Therapy Market Segmentation: By RegionGlobal Gene Therapy market report categorized the information and data according to the major geographical regions like, North America (U.S., Canada, Mexico)Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)Latin America (Brazil, Rest of L.A.)Middle East and Africa (Turkey, GCC, Rest of Middle East)

The Global Gene Therapy Market report covers all dynamic limitations along with Gene Therapy market upsurges, market trends and opportunities, feasibility evaluation, market drivers and restrains, market competitive landscape and guidelines on new investments. The report also covers all the data by market applications, by product types, by geographic regions and information about the suppliers and the investors.

Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Therapy Market Report 2020 (Coronavirus Impact Analysis on Gene Therapy Market)

There are 15 Chapters to display the Global Gene Therapy market:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation

OverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: PESTEL AnalysisChapter 9: Complete profiling and analysis of ManufacturersChapter 10: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expenses.Chapter 11: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 12: Marketing Strategy Analysis, Distributors/TradersChapter 13: Market Effect Factors AnalysisChapter 14: Market ForecastChapter 15: Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source.To access the complete Table of Content click here: @ https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#table_of_contents

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Read the original post:

2020 to 2027 Global Gene Therapy Market Report 2020 COVID 19 Impact Analysis Updated Edition Top Players Include, Kite Pharma, BioVex, Novartis, Spark...

Novartis Launches Initiative to Supply COVID-19 Therapies to Low and Middle-Income Countries – BioSpace

Posted on by

Switzerlands Novartis launched an initiative to assist patients in low-income and lower-middle-income countries in getting access to affordable drugs for COVID-19. Specifically, they are making 15 drugs from its Sandoz division available that can be used to treat symptoms related to COVID-19. They are drugs for gastrointestinal illness, acute respiratory symptoms, pneumonia and septic shock.

Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit. In addition, the initiative will allow the countries to pick therapies in the portfolio that they need. The primary eligibility requirement is that the countries are on the World Banks list of low-income and lower-middle-income (LIC; LMIC) countries.

Access to medicine can be a challenge for patients in low- and lower-middle-income countries and the situation has worsened during COVID-19, said Lutz Hegemann, chief operating officer for Global Health at Novartis. With our COVID-19 portfolio, we wish to help address the additional healthcare demands of the pandemic in the countries we are targeting.

The drugs included in the Novartis COVID-19 Response Portfolio are: Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol and Vancomycin.

The company indicates the portfolio is in addition to the Novartis Access portfolio, which are on- and off-patent medicines against key non-communicable diseases, by way of the local Novartis or Sandoz affiliate.

According to Reuters, Novartis initiative caused the NGO Doctors Without Borders to call for more drug pricing transparency and for the biopharmaceutical industry to follow no profiteering initiatives for new COVID-19 therapies.

Hegemann told Reuters that the company has not had supply chain problems for these drugs, but the focus was on ensuring that the vulnerable healthcare systems in Africa, Asia, South America and Eastern Europe didnt become overwhelmed.

We shouldnt underestimate the stress that COVID puts particularly on fragile health system, Hegemann told Reuters. He said the company planned to work with health authorities, faith-based organizations and NGOs to eliminate markups on drugs. We are not targeting classical commercial distribution channels, but very direct channels.

For the most part, Novartiss branded drugs arent commonly used to treat COVID-19, and its malaria drug hydroxychloroquine has had very mixed results in clinical trials for the disease. But Sandoz is the Swiss companys generics division and has many drugs that are used to treat symptoms of COVID-19 in patients in the hospital. They are typically steroids, antibiotics, an antifungal and lung medication. Most of them have been around for decades and are relatively inexpensive to manufacture.

Novartis should publish the actual at cost prices for these medicines, as well as any costs of R&D and costs of production for all of their medicines, a spokesperson for Doctors Without Borders said. Additionally, we hope that corporations like Novartis will follow similar no profiteering initiatives for any new COVID-19 products.

To date, Novartis has donated $40 million in support of communities globally impacted by the pandemic. They are also involved in two cross-industry research programs, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard, and a COVID-19 directed partnership organized by the Innovative Medicines Initiative (IMI).

It is still supplying hydroxychloroquine for investigator-initiated clinical trials and when governments require it, as appropriate. It is also supporting clinical trials of several of its drugs for COVID-19. In addition, AveXis, its gene therapy unit, inked a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to manufacture its novel genetic COVID-19 vaccine candidate, AAVCOVID.

This initiative builds on our earlier global commitment to keep prices stable for a basket of essential drugs used to treating COVID-19 patients, said Richard Saynor, chief executive officer of Sandoz. The COVID-19 Response Portfolio for low-income and lower-middle-income countries is designed to support governments in treating COVID-19 symptoms before they lead to complications in patients.

See the original post here:

Novartis Launches Initiative to Supply COVID-19 Therapies to Low and Middle-Income Countries - BioSpace

A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog – Endpoints News

Posted on by

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITVs Robert Peston reported that AstraZeneca will publish the Phase I data inThe Lancet.

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZenecas vaccines effect on humans than there was about Modernas before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Read More

Originally posted here:

A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog - Endpoints News

Biotech Firms to Track and Monitor Patients Injected with Stem Cells or Gene Therapy Treatments – The Korea Bizwire

Posted on by

The new business entities should stop the supply and sale of human cells once they are verified to be harmful to human bodies. (Yonhap)

SEOUL, July 16 (Korea Bizwire) New government regulations will require South Korean biotech companies to track and monitor patients who are injected with stem cells or gene therapy treatments.

According to the Ministry of Food and Drug Safety on Wednesday, the Advanced Regenerative Bio Act, enacted to strengthen the safety management of advanced regenerative drugs as well as to facilitate their commercialization through rapid clinical studies, will take effect on Aug. 28.

Under this law, a new type of business called human cell management will be born, which will clear the way for professional management of human and animal cells and tissues in addition to animal organs.

During the process of operation, the new business entities should stop the supply and sale of human cells once they are verified to be harmful to human bodies.

In such cases, all of the human cells concerned should be withdrawn and disposed of.

The law will make it mandatory for biotech companies to register stem cell and gene therapy treatment injection data with the Korea Institute of Drug Safety & Risk Management.

They will also be obliged to report unusual cases and perform long-term tracking and monitoring of the patients.

Advanced regenerative medicine refers to the medical technology of curing, replacing or regenerating damaged cells or issues using human cells.

Kevin Lee (kevinlee@koreabizwire.com)

Excerpt from:

Biotech Firms to Track and Monitor Patients Injected with Stem Cells or Gene Therapy Treatments - The Korea Bizwire

Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust – Endpoints News

Posted on by

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITVs Robert Peston reported that AstraZeneca will publish the Phase I data inThe Lancet.

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZenecas vaccines effect on humans than there was about Modernas before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Read More

More:

Eli Lilly's mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis' drug in the dust - Endpoints News

Need to Get Away? Heres Every Space Tourism Vacation You Can Book Right Now – Observer

Posted on by

Things arent going so great on the planet Earth right now, and travel isnt easy, but if youve got a bit of cash, you can really get away. A number of well-capitalized companies have been hacking away at Space Tourism, or commercially flying regular people into space, and now its on the verge of reality. Thanks to a great deal of financial and human capital put in by organizations ranging from NASA to billionaire-backed startups, we are inches close to turning it into reality.

Space vacation packages come in a wide variety. For beginners, British billionaire Richard Bransons Virgin Galactic is offering a 1.5-hour joy ride to the edge of the Earths atmosphere. NASA is opening the International Space Station to private citizens. And, for hard-core space explorers, Elon Musks SpaceX has promised to fly you to the Moon (for a hefty price) in as soon as 2023.

Below weve put together the latest statuses of various space tourism projects in the market.

Destination: Edge of the Earths atmosphere

Price: $250,000 per person

Earliest available time: late 2020

Virgin Galactics supersonic spaceplane, VSS Unity, will fly passengers up to 100 kilometers (62 miles) above sea level, which is right above the Krmn Line dividing the Earths atmosphere and outer space. From there, passengers will get a stunning view of the Earths curvature. Then, during the descent, they will experience several minutes of weightlessness like a true astronaut.

VSS Unity has completed two successful human test flights and is in its final stage of testing. Virgin Galactic plans to fly its first paying customer, possibly the companys founder Richard Branson himself, as soon as this year.

Destination: The edge of the Earths atmosphere

Price: $200,000 and $300,000

Earliest available time: unknown

Blue Origin, owned by Amazon CEO Jeff Bezos, is developing a suborbital tourism program similar to Virgin Galactics but using a vertical-takeoff, vertical-landing (VTVL) rocket-capsule system called New Shepard. The New Shepard spacecraft has successfully flown above the Krmn Line and returned to the ground.

Blue Origin had planned to launch its first human test flight in 2019 and begin selling commercial tickets (reportedly priced between $200,000 and $300,000) soon after. Yet, the plan was quietly canceled last year. The company has yet to make public statements about new test and rollout dates.

Destination: International Space Station

Price: $35,000 per night

Earliest available time: late 2020

In June 2019, NASA unveiled its grand plan to allow private citizens to fly to the International Space Station under the agencys Commercial Crew Program. Passengers will fly in either SpaceXs Crew Dragon spacecraft or Boeings Starlinervessel.

The Crew Dragon recently completed its final crewed test and is ready to be deployed for commercial missions. NASA has said it will allow up to two private trips to the ISS a year, each lasting up to 30 days. The total cost of the trip would be around $50 million per person, the agency said.

Destination: the Moon

Price: Not a trivial amount

Earliest available time: 2023

Elon Musks rocket company SpaceX has the ultimate space vacation offering: a personalized trip to the Moon. The package has one committing customer so far: Japanese fashion mogul Yusaku Maezawa, who signed up for the trip in September 2018 and has put down an undisclosed deposit. Musk has said the full ticket price is not a trivial amount.

SpaceX is currently building prototypes for the rocket (Big Falcon Rocket (BFR) rocket) and spaceship (Starship) that will fly Maezawa to the Moon. If all tests go according to the plan, a human launch could take place as early as 2023.

Link:

Need to Get Away? Heres Every Space Tourism Vacation You Can Book Right Now - Observer

‘They’re really good men’: Victoria Beckham is proud of her sons – Opelika Auburn News

Posted on by

Victoria Beckham feels "really proud" of her sons.

The 46-year-old designer has Brooklyn, 21, Romeo, 17, and Cruz, 15, with her husband David Beckham - with whom she also has nine-year-old daughter Harper - and has said she couldn't be happier with the way her sons are growing up, as they're "turning out to be really good men".

She said: "I feel really proud of our boys because they are turning out to be really good men. They work hard and they're kind, and being kind is key now. I think everybody should be kind - there are so many horrible things going on in the world. With regards to the boys they always have to have respect for themselves, for others, for girls. Our boys have always had the utmost respect for everyone. They have always been like that."

And for the former Spice Girls star, motherhood is her greatest achievement.

She added during an interview with photographer Alexi Lubimorski for his YouTube series: "Being a mum is the most important job in the world. I love what I do professionally and I take it very seriously but there is nothing more serious than having children. It's your responsibility to bring up really good, good people so I take that responsibility seriously. I try to be the best mum, I try to be the best wife, and I try and be the best professional."

Victoria has been staying at home with her family amid the coronavirus pandemic, and recently said her time in lockdown has been "precious".

She explained: "While working from home, we've been on walks every day as a family. How often would we all go on a walk together normally? Usually there's a conference call or a work meeting or someone is travelling abroad. These times are precious.

View post:

'They're really good men': Victoria Beckham is proud of her sons - Opelika Auburn News

Commentary: Conservatives will defeat themselves if they don’t wake up to social media reform – The Daily World

Posted on by

By Rudolph Bush

The Dallas Morning News

In a move that interested few and mattered less, Texas state Rep. Jonathan Stickland announced to Twitter on July 2 that enough was enough. He was leaving the platform for a place where he felt he could express himself full bore without the liberal idiots with mob mentality that have taken over here.

The Bedford, Texas, Republican promised to check his account infrequently, a pledge that turned out to be too good to be true since his Twitter thumb has remained pretty active in the days that followed.

But like other conservatives with a libertarian streak, most prominently Sen. Ted Cruz, Stickland said he was decamping for something called parler.com, a place apparently less hostile to his political persuasions but hardly a stranger to mob-think.

I dont know much about Parler. A brief stroll suggested it wont be a regular stop. I do know a thing or two about Twitter, and Stickland is partly right. Whatever you dont like, Twitter serves it in stinking heaps.

Mob mentality? Check. Hate speech? Check. Racism? Check. Anonymous libel? Check. Preening moralism and virtue signaling? Check and check. Trolls, bots and fake accounts pitting people in constant battle? You have come to the right place.

The problem of thinking like Stickland and Cruz and even President Donald Trumps reelection campaign is that it casts the social media problem as a political one. Twitter is becoming too liberal or too intolerant of conservatives, or so goes the argument.

But this isnt a conservative or liberal problem. This is a human social problem now, and one we better figure out how to fix fast, because it is giving us a political culture that promotes the worst, scares away the best and tears just about everything it gets in its maw to pieces.

Stickland isnt an interesting politician. A stock character from tea party central casting, he has consistently and successfully worked at making a joke of his office and its duty to legislate. Except for his habit of crippling good bills, his fellow conservatives stopped taking him seriously years ago.

But his social media situation is instructive as to what Big Techs platforms are doing to our national conversation and to why we cant fix social media the way it appears we are going to try.

The way things are going, free speech is going to be diminished if we let the platforms get their way. And, in the short term at least, conservatives will probably get the brunt of it.

In the long run, though, we are in danger of turning over the decision of what speech is and is not acceptable to profit-driven companies that do all they can to keep us glued to our screens.

Lets look at how this is playing out and why we need to stop it.

Last week, Facebook undisputed king of all social media had to face the music of a civil rights audit it paid for that found the platform is not sufficiently attuned to the depth of concern on the issue of polarization and the way that the algorithms used by Facebook inadvertently fuel extreme and polarizing content.

Instead of enabling free speech, Facebook privileges certain voices over less powerful voices, the auditors wrote.

The answer, according to the audit, is to somehow neutralize or disempower extreme and polarizing content issuing from privileged voices.

If that sounds like a good solution, recognize that you can put a lot of ideas and voices into those categories, and what constitutes extreme and polarizing shifts with the winds.

The solution that Facebook appears to be driving at is to remove content that might concern some people even as its removal concerns others. In response to the audit, Facebook has already removed posts and pages associated with Trump political operative turned felon Roger Stone and the far-right Proud Boys group.

Thats low-hanging fruit. And even that has been controversial. It will only get harder to parse what does and does not constitute hate speech or polarizing speech. Revolutionary Thomas Paine and abolitionist William Lloyd Garrison were polarizing, after all.

If we leave it to social media platforms to decide what is and isnt acceptable, we will only continue to be damaged as a democracy.

Even if it were possible for these companies to perfectly judge what should and shouldnt be posted (and it isnt), they have proved over time that this is not something they are going to do. As Shoshana Zuboff details exquisitely in her crucial book The Age of Surveillance Capitalism, these companies have acted at every turn to create products that deceive and divide in the name of profit.

Conservatives are hurting their own cause in this case. Cruz has been outspoken on the matter. But his instinct is toward libertarianism and preventing platforms from policing speech in any way. When he joined Parler, he said, the platform gets what free speech is all about.

That is a self-defeating strategy. Preaching to the choir gets awfully dull, and Cruz has hardly given up Twitter where his audience is larger and he gets in the sparring he seems to cherish.

If things continue on the path they are going, conservatives will have much to worry about when it comes to social medias selection of what is and isnt acceptable speech.

But they would be wise to join those on the left who post-Russian electoral interference still have a strong appetite for reining in the way America regulates platforms. And they had better act fast, before the entire left recognizes the advantage that is about to come its way from social medias big self-correction.

For too long, these companies have enjoyed freedom from liability for what people post on their sites even as their products have damaged our democracy. The wise legislator is coming to understand how that carte blanche has narrowed and cheapened the internet, when it was supposed to broaden and democratize it.

There has to be a reconnection to responsibility for what goes up that is governed the way we have always governed speech through threat of libel.

Would it substantially change the way platforms function? Of course.

Would that be what the country needs?

Take a run through Twitter today and answer that question for yourself.

Rudolph Bush is deputy editorials editor for The Dallas Morning News.

Continue reading here:

Commentary: Conservatives will defeat themselves if they don't wake up to social media reform - The Daily World